metaPreg - Ethosuximide (All indications) during pregnancy

Ethosuximide (All indications) updated on 04-22-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	2.66 [1.01, 7.00]	0%	8 studies	49,676	64	not evaluable	ROB	4.77 [1.12; .]
Major congenital malformations	2.87 [1.05, 7.84]	0%	8 studies	49,670	64	not evaluable	ROB	5.19 [1.29; .]
Congenital heart defects	4.26 [0.38, 47.27]	0%	2 studies	9	12	not evaluable	ROB	-
Hypospadias	4.12 [0.37, 45.30]	0%	2 studies	9	12	not evaluable	ROB	-
Neural Tube Defects	18.80 [1.26, 279.89]	0%	2 studies	2	12	not evaluable	ROB	37.09 [1.84; .]
7 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
3 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Withdrawal syndrome / Neonatal abstinence syndrome / Poor neonatal adaptation	-	-	0 study					-
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Intrauterine deaths (as a whole or unspecified)	-	-	0 study					-
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study